» Articles » PMID: 31527133

Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma

Overview
Journal Cancer Discov
Specialty Oncology
Date 2019 Sep 19
PMID 31527133
Citations 234
Authors
Affiliations
Soon will be listed here.
Abstract

Renal cell carcinoma stands out as one of the most immune-infiltrated tumors in pan-cancer comparisons. Features of the tumor microenvironment heavily affect disease biology and may affect responses to systemic therapy. With evolving frontline options in the metastatic setting, several immune checkpoint blockade regimens have emerged as efficacious, and there is growing interest in characterizing features of tumor biology that can reproducibly prognosticate patients and/or predict the likelihood of their deriving therapeutic benefit. Herein, we review pertinent characteristics of the tumor microenvironment with dedicated attention to candidate prognostic and predictive signatures as well as possible targets for future drug development. SIGNIFICANCE: Tumor microenvironment features broadly characterizing angiogenesis and inflammatory signatures have shown striking differences in response to immune checkpoint blockade and antiangiogenic agents. Integration of stromal and immune biomarkers may hence produce predictive and prognostic signatures to guide management with existing regimens as well as future drug development.

Citing Articles

Glycogen metabolism genes as a molecular signature for subtyping, prognostic prediction, and immunotherapy selection in clear cell renal cell carcinoma.

Ni F, Tan X, Zhang J, Guo T, Yuan Z, Wang X Clin Exp Med. 2025; 25(1):61.

PMID: 39961952 PMC: 11832626. DOI: 10.1007/s10238-025-01592-4.


Tumor-initiating and metastasis-initiating cells of clear-cell renal cell carcinoma.

Pham D, Hsu T J Biomed Sci. 2025; 32(1):17.

PMID: 39920694 PMC: 11806631. DOI: 10.1186/s12929-024-01111-9.


Potential prognostic and immunologic significances of ADAM8 in clear cell renal cell carcinoma.

Chu M, Zhang Z, Wang Z, Li Z, Guo Y Medicine (Baltimore). 2025; 104(5):e41375.

PMID: 39889162 PMC: 11789870. DOI: 10.1097/MD.0000000000041375.


Identification and validation of prognostic biomarkers in ccRCC: immune-stromal score and survival prediction.

Lyu F, Zhong Y, He Q, Xiao W, Zhang X BMC Cancer. 2025; 25(1):148.

PMID: 39871215 PMC: 11771106. DOI: 10.1186/s12885-025-13534-0.


Bioinformatics analysis of mitochondrial metabolism-related genes demonstrates their importance in renal cell carcinoma.

Ahmadi M, Motallebinezhad M, Mousavi P, Miladipour A, Fooladgar S, Ghafouri-Fard S Discov Oncol. 2025; 16(1):28.

PMID: 39789365 PMC: 11717778. DOI: 10.1007/s12672-025-01780-4.


References
1.
Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

2.
Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay R, Luoma A . A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018; 359(6377):770-775. PMC: 5953516. DOI: 10.1126/science.aao1710. View

3.
Yin Q, Hung S, Wang L, Lin W, Fielding J, Rathmell W . Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell-Renal-Cell-Carcinoma: Proof-of-Concept Study. Sci Rep. 2017; 7:43356. PMC: 5335708. DOI: 10.1038/srep43356. View

4.
Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

5.
Miao D, Margolis C, Gao W, Voss M, Li W, Martini D . Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018; 359(6377):801-806. PMC: 6035749. DOI: 10.1126/science.aan5951. View